The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study
Authors:
- Allan YoungAllan Young
- Knut EngedalKEKnut Engedal
- John O'BRienJOJohn O'BRien
- Geir SelbaekGSGeir Selbaek
- Ane-Victoria IdlandAIAne-Victoria Idland
- Leiv-Otto WatneLWLeiv-Otto Watne
- Tom BorzaTBTom Borza
- Mariia BocharovaMBMariia Bocharova
Preprint
- 16 May 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Late-life depression (LLD) has been linked to increased likelihood of subsequent dementia, although mechanisms responsible for this association remain largely unknown. One feature frequently observed in both LLD and dementia is elevated levels of plasma inflammatory markers. PRODE (Prognosis of Depression in the Elderly) is a prospective naturalistic study of patients with LLD (N=152; aged 60+). Patients were followed up for 3 years; follow-up data was available for 138 patients, and 36 (26.1%) developed dementia by year 3. Plasma inflammatory markers data were available for 136 patients at baseline for the following range of cytokines and chemokines: IL-1β, IL-1ra, IL-6, IL-10, IL-17a, IL-18, IL-33, TNFα, CD40L, IFN-γ, CCL-2 and CCL-4. Levels of plasma inflammatory markers were compared between 136 LLD patients and healthy controls (n=103), using first multiple linear regression (inflammatory markers as outcome) with stepwise adjustment, and then binary logistic regression with depression status (LLD vs controls) as outcome. Further, we explored whether inflammatory markers and clinical characteristics of LLD (age of onset, course) predicted progression from LLD to dementia using Cox regression. Levels of IL-1ra, IFN-γ, CCL-2, CCL-4 and IL-17a were significantly higher in LLD patients compared to controls. However, none of the inflammatory markers predicted progression from LLD to dementia. Among clinical features, only poor response to treatment significantly predicted higher risk of progression to dementia. In summary, this study replicated previous findings of an increase in inflammatory markers in LLD but did not find evidence they had increased risk of developing future dementia.Keywords
All Related Versions
- Version 1, 2023-05-16, Research Square
- Published version: Molecular Psychiatry, 30 (7), 3029.
This publication has 59 references indexed in Scilit:
- The validity of the Montgomery–Aasberg depression rating scale as a screening tool for depression in later lifeJournal of Affective Disorders, 2012
- The neurobiology of depression in later-life: Clinical, neuropsychological, neuroimaging and pathophysiological featuresProgress in Neurobiology, 2012
- Blood Inflammatory Proteins and Risk of Incident Depression in the ElderlyDementia and Geriatric Cognitive Disorders, 2010
- Interleukin-1 Receptor Antagonist and Incident Depressive Symptoms Over 6 Years in Older Persons: The InCHIANTI StudyBiological Psychiatry, 2009
- Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-AnalysisPsychosomatic Medicine, 2009
- The state of mental health in old‐age across the ‘old’ European Union – a systematic reviewActa Psychiatrica Scandinavica, 2005
- Validation of a 26-Point Telephone Version of the Mini-Mental State ExaminationJournal of Geriatric Psychiatry and Neurology, 2004
- The Halstead—Reitan Neuropsychological Test Battery: research findings and clinical application2001
- Trail making test: normative values from 287 normal adult controlsThe Italian Journal of Neurological Sciences, 1996
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979